Compare AbCellera Biologics Inc (ABCL) vs Nvidia Corp (NVDA) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

NVIDIA (NVDA) trades at $204.15, up 4.4% in the last 24 hours, with a bearish technical signal but strong fundamental performance. The stock shows robust revenue growth, with 2025 revenue reaching $130.50B and net income of $72.88B, supported by high profitability margins. Recent earnings have consistently beaten estimates, and analyst consensus remains strongly bullish with a $324.95 price target. However, technical indicators highlight resistance near $207 and support at $185, suggesting near-term consolidation.

The outlook for NVDA is positive due to its leadership in AI chips and accelerating revenue growth, though risks include increased competition and market volatility. Investor sentiment is mixed, with media highlighting growth potential but also concerns over peak AI spending. Institutional activity shows some trimming of positions, yet the majority of analysts maintain buy ratings, indicating confidence in long-term value.